xCellSense® measures drug response ex vivo in primary cells from dogs with naturally occurring lymphoma and leukemia — for veterinary oncology programs and for translational teams studying cancer biology across species.
Scope a Canine Study
Canine lymphoma and leukemia arise spontaneously in pet dogs and are commonly treated with CHOP-based chemotherapy, as in human lymphoma. Primary canine cells let you measure drug response in naturally occurring disease — whether you are developing a veterinary therapy or studying cancer biology across species.
Diffuse large B-cell lymphoma, the most common canine lymphoma, shares key clinical and molecular features with its human counterpart. ImpriMed brings years of routine canine lymphoma testing and peer-reviewed research to your study design.
1
Drug sensitivity in primary canine cells
Dose-response profiling of your candidate in primary canine lymphoma or leukemia cells, with controls and comparators, such as CHOP components, chosen for your study. Sample access is study-specific, subject to availability and appropriate consent.
2
Combination profiling
Test your candidate with CHOP components or other partners and quantify combination effects with computational synergy scoring.
3
Immunophenotyping and target expression
Characterize tumor and immune cell populations and your target's expression by flow cytometry with canine-reactive antibody panels.
4
Exploratory molecular correlation
Where material allows, relate drug response to genomic or transcriptomic features to generate biomarker hypotheses.
ImpriMed's veterinary service has reported more than 25,000 canine and feline lymphoma tests, with 340+ hospitals contributing real-world clinical evidence. Peer-reviewed research links ex vivo drug response and immunophenotype to chemotherapy response in canine lymphoma (Veterinary and Comparative Oncology, 2021).
Conversations with veterinary oncologists and researchers on the role of naturally occurring cancers in drug development, from ImpriMed's Veterinary Cancer Pioneers Podcast.
Early evidence of activity in naturally occurring disease, a view of patient-to-patient variability, and data to prioritize candidates, combinations, and next studies.
Key Deliverables
Share your candidate, modality, and question. A scientist will assess fit, including sample access and target cross-reactivity, and propose a study design and timeline.
